Document:

<PAGE>

           FORM OF NON-EMPLOYEE DIRECTOR STOCK SUBSCRIPTION AGREEMENT
           ----------------------------------------------------------

     NON-EMPLOYEE DIRECTOR STOCK SUBSCRIPTION AGREEMENT, dated as of October __,
1999, between Dynatech Corporation, a Delaware corporation (the "Company"), and
the Purchaser whose name appears on the signature page hereof (the "Purchaser").

                              W I T N E S S E T H:
                              - - - - - - - - - -

     WHEREAS, the Company desires to encourage and enable Directors to acquire a
proprietary interest in the Company;

     WHEREAS, it is anticipated that providing such persons with a direct stake
in the Company's welfare will assure a closer identification of their interests
with those of the Company and stockholders, thereby stimulating their efforts on
the Company's behalf and strengthening their desire to remain with the Company;

     WHEREAS, the Board of Directors of the Company (the "Board") has adopted
the Dynatech Corporation Directors Stock Purchase Plan (the "Plan") and,
pursuant to the Plan, has granted to the Purchaser the right to purchase the
aggregate number of shares of Common Stock ("Common Stock"), of the Company set
forth on the signature page hereof (each a "Share" and, collectively, the
"Shares") at the purchase price provided for herein; and

     WHEREAS, the Purchaser desires to subscribe for and purchase from the
Company the Shares, at a purchase price of $3.25 per share, such price being the
fair market value of a share of Common Stock, as determined in good faith by the
Board on May 18, 1999;

     WHEREAS, the Company desires to sell the Shares to the Purchaser on the
terms and subject to the conditions set forth herein;

     NOW, THEREFORE, to implement the foregoing and in consideration of the
mutual promises, covenants and agreements contained herein, the parties hereto
hereby agree as follows:

     1. Purchase and Sale of Common Stock.
        ---------------------------------

     (a) Purchase of Common Stock. Subject to all of the terms and conditions of
         ------------------------
this Agreement, the Purchaser hereby subscribes for and shall purchase, and the
Company shall sell to the Purchaser, the Shares, at a purchase price of $3.25
per Share, at the Closing provided for in Section 2(a) hereof. Notwithstanding
anything to
<PAGE>

the contrary, the Company shall have no obligation to sell any Common Stock to
any person who will not be a director of the Company immediately following the
Closing.

     (b) Consideration. Subject to all of the terms and conditions of this
         -------------
Agreement, the Purchaser shall deliver to the Company at the Closing referred to
in Section 2(a) hereof, immediately available funds in the amount of the
aggregate purchase price set forth on the signature page hereof.

     2. Closing.
        -------

     (a) Time and Place. Except as otherwise mutually agreed by the Company and
         --------------
the Purchaser, the closing (the "Closing") of the transaction contemplated by
this Agreement shall be held at the offices of Dynatech Corporation, 3 New
England Executive Park, Burlington, Massachusetts 01803 on or about
____________, 1999.

     (b) Delivery by the Company. At the Closing, the Company shall deliver to
         -----------------------
the Purchaser a stock certificate registered in the Purchaser's name and
representing the Shares, which certificate shall bear the legends set forth in
Section 3(b) hereof.

     (c) Delivery by the Purchaser. At the Closing, the Purchaser shall deliver
         -------------------------
to the Company the consideration referred to in Section 1(b) hereof.

     3. Purchaser's Representations, Warranties and Covenants.
        -----------------------------------------------------

     (a) Investment Intention. The Purchaser represents and warrants that the
         --------------------
Purchaser is acquiring the Shares solely for the Purchaser's own account for
investment and not with a view to or for sale in connection with any
distribution thereof. The Purchaser agrees that the Purchaser will not, directly
or indirectly, offer, transfer, sell, pledge, hypothecate or otherwise dispose
of any of the Shares (or solicit any offers to buy, purchase or otherwise
acquire or take a pledge of any Shares), except in compliance with the
Securities Act of 1933, as amended (the "Securities Act"), and the rules and
regulations of the Securities and Exchange Commission thereunder, and in
compliance with applicable state securities or "blue sky" laws. The Purchaser
further understands, acknowledges and agrees that none of the Shares may be
transferred, sold, pledged, hypothecated or otherwise disposed of (i) unless the
provisions of Section 4 shall have been complied with or have expired, (ii)
unless (A) such disposition is pursuant to an effective registration statement
under the Securities Act, (B) the Purchaser shall have delivered to the Company
an opinion of counsel, which opinion and counsel shall be reasonably
satisfactory to the Company, to the effect that such disposition is exempt from
the provisions of Section 5 of the Securities Act or (C) a no-action letter from
the Securities and Exchange Commission, reasonably satisfactory to the Company,

                                       2
<PAGE>

shall have been obtained with respect to such disposition and (iii) unless such
disposition is pursuant to registration under any applicable state securities
laws or an exemption therefrom.

     (b) Legends. The Purchaser acknowledges that the certificate or
         -------
certificates representing the Shares shall bear the following legends or other
appropriate legends:

          "THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE
          PROVISIONS OF A NON-EMPLOYEE DIRECTOR STOCK SUBSCRIPTION AGREEMENT,
          DATED AS OF OCTOBER __, 1999, AS THE SAME MAY BE AMENDED FROM TIME TO
          TIME, AND NEITHER THIS CERTIFICATE NOR THE SHARES REPRESENTED BY IT
          ARE ASSIGNABLE OR OTHERWISE TRANSFERABLE EXCEPT IN ACCORDANCE WITH THE
          PROVISIONS OF SUCH NON-EMPLOYEE DIRECTOR  STOCK SUBSCRIPTION
          AGREEMENT, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE
          COMPANY.  THE SHARES REPRESENTED BY THIS CERTIFICATE ARE ENTITLED TO
          THE BENEFITS OF AND ARE BOUND BY THE OBLIGATIONS SET FORTH IN A
          REGISTRATION RIGHTS, DATED AS OF MAY 21, 1998, AMONG THE COMPANY AND
          CERTAIN STOCKHOLDERS OF THE COMPANY, A COPY OF WHICH IS ON FILE WITH
          THE SECRETARY OF THE COMPANY AS THE SAME MAY BE AMENDED FROM TIME TO
          TIME."

          "THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
          PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
          ACT OF 1933, AS AMENDED, OR QUALIFIED UNDER ANY STATE SECURITIES LAWS
          AND MAY NOT BE TRANSFERRED, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE
          DISPOSED OF UNLESS (i) (A) SUCH DISPOSITION IS PURSUANT TO AN
          EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS
          AMENDED, (B) THE HOLDER HEREOF SHALL HAVE DELIVERED TO THE COMPANY AN
          OPINION OF COUNSEL, WHICH OPINION AND COUNSEL SHALL BE REASONABLY
          SATISFACTORY TO THE COMPANY, TO THE EFFECT THAT SUCH DISPOSITION IS
          EXEMPT FROM THE PROVISIONS OF SECTION 5 OF SUCH ACT OR (C) A NO-ACTION
          LETTER FROM THE SECURITIES AND EXCHANGE COMMISSION, REASONABLY
          SATISFACTORY TO COUNSEL FOR THE

                                       3
<PAGE>

          COMPANY, SHALL HAVE BEEN OBTAINED WITH RESPECT TO SUCH DISPOSITION AND
          (ii) SUCH DISPOSITION IS PURSUANT TO REGISTRATION UNDER ANY APPLICABLE
          STATE SECURITIES LAWS OR AN EXEMPTION THEREFROM."

     (c) Securities Law Matters. The Purchaser acknowledges receipt of advice
         ----------------------
from the Company that (i) the Shares have not been registered under the
Securities Act or qualified under any state securities or "blue sky" laws, (ii)
the Shares must be held indefinitely and the Purchaser must continue to bear the
economic risk of the investment in the Shares unless the Shares are subsequently
registered under the Securities Act and such state laws or an exemption from
registration is available, (iii) when and if the Shares may be disposed of
without registration in reliance upon Rule 144 promulgated under the Securities
Act ("Rule 144"), such disposition can be made only in limited amounts in
accordance with the terms and conditions of such Rule, (iv) a restrictive legend
in the form heretofore set forth shall be placed on the certificates
representing the Shares and (v) a notation shall be made in the appropriate
records of the Company indicating that the Shares are subject to restrictions on
transfer set forth in this Agreement and appropriate stop-transfer restrictions
will be issued to the Company's stock transfer agent with respect to the Shares.

     (d) Compliance with Rule 144. If any of the Shares are to be disposed of
         ------------------------
in accordance with Rule 144, the Purchaser shall transmit to the Company an
executed copy of Form 144 (if required by Rule 144) no later than the time such
form is required to be transmitted to the Securities and Exchange Commission for
filing and such other documentation as the Company may reasonably require to
assure compliance with Rule 144 in connection with such disposition.

     (e) Ability to Bear Risk. The Purchaser represents and warrants that (i)
         --------------------
the financial situation of the Purchaser is such that the Purchaser can afford
to bear the economic risk of holding the Shares for an indefinite period and
(ii) the Purchaser can afford to suffer the complete loss of the Purchaser's
investment in the Shares.

     (f) Questionnaire. The Purchaser agrees to furnish such documents and
         -------------
comply with such reasonable requests of the Company as may be necessary to
substantiate the Purchaser's status as a qualifying investor in connection with
the private offering of shares of Common Stock to the Purchaser. The Purchaser
represents and warrants that all information contained in such documents and any
other written materials concerning the status of the Purchaser furnished by the
Purchaser to the Company in connection with such requests will be true, complete
and correct in all material respects.

     (g) Access to Information. The Purchaser represents and warrants that (i)
         ---------------------
the Purchaser has carefully reviewed the Amended and Restated Offering

                                       4
<PAGE>

Memorandum, dated October 1999, and the other materials furnished to the
Purchaser in connection with the transaction contemplated hereby, (ii) the
Purchaser has been granted the opportunity to ask questions of, and receive
answers from, representatives of the Company concerning the terms and conditions
of the purchase of the Shares and to obtain any additional information that the
Purchaser deems necessary to verify the accuracy of the information contained in
such materials and (iii) the Purchaser's knowledge and experience in financial
and business matters is such that the Purchaser is capable of evaluating the
risks of the investment in the Shares.

     (h) Registration; Restrictions on Sale upon Public Offering. The Purchaser
         -------------------------------------------------------
shall be entitled to the rights and subject to the obligations created under the
Registration Rights Agreement, dated as of May 21, 1999, among the Company,
Clayton, Dubilier & Rice Fund V Limited Partnership (the "Fund") and certain
stockholders of the Company (the "Registration Rights Agreement"), to the extent
set forth therein, and the Shares shall be considered Registrable Securities
thereunder. The Purchaser agrees that, in the event that the Company files a
registration statement under the Securities Act with respect to an underwritten
public offering of any shares of its capital stock, the Purchaser will not
effect any public sale or distribution of any shares of the Common Stock (other
than as part of such underwritten public offering), including but not limited
to, pursuant to Rule 144 or Rule 144A ("Rule 144A") under the Securities Act,
during the 20 days prior to and the 180 days after the effective date of such
registration statement.

     4. Restrictions on Disposition of Shares. For 18 months from the date of
        -------------------------------------
this Agreement, neither the Purchaser nor any of the Purchaser's heirs or
representatives shall sell, assign, transfer, pledge or otherwise directly or
indirectly dispose of or encumber any of the Shares to or with any other person,
firm, trust, association, corporation or entity (including, without limitation,
transfers to any other holder of the Company's capital stock, dispositions by
gift, by will, by a corporation as a distribution in liquidation and by
operation of law other than a transfer of Shares by operation of law to the
estate of the Purchaser upon the death of the Purchaser, provided that such
                                                         --------
estate shall be bound by all of the provisions of this Agreement), provided that
                                                                   --------
such restrictions shall not apply to any such disposition of the Shares pursuant
to Section 6 of this Agreement. The restrictions contained in this Section 4
shall terminate in the event that an underwritten public offering of the Common
Stock led by one or more underwriters at least one of which is an underwriter of
nationally recognized standing (a "Public Offering") has been consummated and
shall not apply to a sale to the underwriters as part of a Public Offering. Any
transfer or attempted transfer of the Shares in violation of this Section 4
shall be null and void ab initio, and the Company shall not register, recognize
or give effect to any such transfer or attempted transfer, nor shall the
intended transferee acquire any rights in such Shares. The Purchaser
acknowledges and agrees that the restrictions on transfer of the Shares
contained in this Section 4 relate to special, unique and

                                       5
<PAGE>

extraordinary matters and that a violation of any of the terms of such
restrictions will cause the Company irreparable injury for which adequate
remedies are not available at law. Accordingly, the Purchaser agrees that the
Company shall be entitled to an injunction, restraining order or such other
equitable relief (without the requirement to post bond) as a court of competent
jurisdiction may deem necessary or appropriate to restrain the Purchaser from
committing any violation of the terms of such restrictions. These injunctive
remedies are cumulative and in addition to any other rights and remedies the
Company may have.

     5. Representations and Warranties of the Company. The Company represents
        ---------------------------------------------
and warrants to the Purchaser that (a) the Company has been duly incorporated
and is an existing corporation in good standing under the laws of the
jurisdiction of its incorporation, (b) this Agreement has been duly authorized,
executed and delivered by the Company and constitutes a valid and legally
binding obligation of the Company enforceable against the Company in accordance
with its terms, (c) the Shares, when issued, delivered and paid for in
accordance with the terms hereof, will be duly and validly issued, fully paid
and nonassessable, and free and clear of any liens or encumbrances other than
those created pursuant to this Agreement, or otherwise in connection with the
transactions contemplated hereby and upon his acquisition of the Shares, the
Purchaser will become entitled to the rights and subject to the obligations of a
holder of "Registrable Securities" as set forth in the Registration Rights
Agreement.

     6. Tag-Along Rights. So long as there has not been an underwritten public
        ----------------
offering of the Common Stock led by at least one underwriter of nationally
recognized standing (a "Public Offering"), the Fund hereby agrees not to make
any sale or transfer of Common Stock owned by the Fund which would constitute a
Qualifying Sale, except pursuant to the following provisions of this Section 6:

     (a) At least 30 days prior to making any sale or transfer of Common Stock
which would constitute a Qualifying Sale, the Fund will deliver a written notice
(the "Sale Notice") to the Company and the Purchaser. The Sale Notice will fully
disclose the identity of the prospective transferee and the terms and conditions
of the proposed Qualifying Sale. The Fund agrees not to consummate any such
proposed Qualifying Sale until at least 30 days after the Sale Notice has been
delivered to the Purchaser, unless the Fund has received notice from the
Purchaser indicating whether or not the Purchaser has elected to participate in
such Qualifying Sale and the number of shares to be sold by the Purchaser has
been finally determined pursuant hereto prior to the expiration of such 30-day
period. The Purchaser may elect to participate in the proposed Qualifying Sale
by delivering written notice to the Fund and the Company within 30 days after
receipt of the Sale Notice. If the Purchaser elects to participate in such
proposed Qualifying Sale, the Purchaser will be entitled to sell in such
Qualifying Sale, at the same price and on the same terms as the Fund, a number
of Shares equal to

                                       6
<PAGE>

the product of (i) the quotient determined by dividing (A) the percentage of the
then outstanding Common Stock represented by the shares of Common Stock then
held by the Purchaser by (B) the aggregate percentage of the then outstanding
Common Stock represented by the Common Stock then held by the Fund and the
aggregate Common Stock held by those directors and employees of the Company or a
subsidiary (including the Purchaser) who elect to participate in such proposed
Qualifying Sale pursuant to the terms of their respective agreements and (ii)
the number of shares of Common Stock such transferee has agreed to purchase in
the proposed Qualifying Sale (or, in the case of a Qualifying Sale within the
meaning of clause (ii) of Section 6(b), the Excess Number of shares which such
transferee has agreed to purchase).

     (b) The term "Qualifying Sale" shall mean (i) any sale or transfer of
Common Stock proposed to be made by the Fund at any time after the Fund has sold
or transferred in the aggregate at least the Qualifying Number of shares of
Common Stock or (ii) in the event that prior to the sale or transfer by the Fund
of an aggregate of the Qualifying Number of shares of Common Stock, the Fund
proposes to sell or transfer a number of shares of Common Stock which when
combined with any prior sales or transfers of such shares by the Fund exceeds
the Qualifying Number, the sale or transfer of a number of shares (the "Excess
Number") equal to the excess of (A) the sum of any shares previously sold or
transferred by the Fund and the aggregate number of shares proposed to be sold
or transferred in such contemplated sale, over (B) the Qualifying Number of
shares. In determining whether there is a Qualifying Sale, equitable adjustments
shall be made to reflect any stock split, stock dividend, stock combination,
recapitalization or similar transaction. The term "Qualifying Number" shall mean
5,539,539 shares of Common Stock (excluding any sales or transfers by the Fund
to any director or employee of the Company or a subsidiary of the Company).

     (c) The obligation of the Fund and the rights of the Purchaser pursuant to
this Section 6 will not apply to any sale or transfer by the Fund pursuant to a
distribution to the public (whether pursuant to a Public Offering or pursuant to
Rule 144 or otherwise (but not pursuant to Rule 144A or any successor
provision). Any shares referred to, or covered by any sale, transfer or
distribution referred to, in the preceding sentence shall not be included in the
computation of Qualifying Sale.

     (d) The Fund acknowledges that the Purchaser would be irreparably damaged
in the event of a breach or a threatened breach by the Fund of any of its
obligations under this Section 6 and the Fund agrees that, in the event of a
breach or a threatened breach by the Fund of any such obligation, the Purchaser
shall, in addition to any other rights and remedies available to him or her in
respect of such breach, be entitled to an injunction from a court of competent
jurisdiction (without any requirement to post bond) granting it specific
performance by the Fund of its obligations under this Section 6. In the event
that the Purchaser shall file suit to enforce the covenants

                                       7
<PAGE>

contained in this Section 6 (or obtain any other remedy in respect of any breach
thereof) and prevails in such suit the Purchaser shall be entitled to recover
from the Company the costs incurred by the Purchaser in conducting the suit,
including reasonable attorney's fees and expenses.

     7. Miscellaneous.
        -------------

     (a) Notices. All notices and other communications required or permitted to
         -------
be given under this Agreement shall be in writing and shall be deemed to have
been given if delivered personally or sent by certified or express mail, return
receipt requested, postage prepaid, or by any recognized international
equivalent of such mail delivery, to the Company, the Fund or the Purchaser, as
the case may be, at the following addresses or to such other address as the
Company, the Fund or the Purchaser, as the case may be, shall specify by notice
to the others:

     (i)   if to the Company, to it at:

               Dynatech Corporation
               3 New England Executive Park
               Burlington, MA 01803
               Attention:  General Counsel
               ---------

     (ii)  if to the Purchaser, to the Purchaser at the address set forth on the
           signature page hereof.

     (iii) if to the Fund, to:

               Clayton, Dubilier & Rice
                  Fund V Limited Partnership
               1403 Fulk Road, Suite 106
               Wilmington, Delaware 19803
               Attention:  Brian D. Finn
               ---------

All such notices and communications shall be deemed to have been received on the
date of delivery if delivered personally or on the third business day after the
mailing thereof.  Copies of any notice or other communication given under this
Agreement shall also be given to:

               Clayton, Dubilier & Rice, Inc.
               375 Park Avenue, 18th Floor
               New York, New York  10152
               Attention:  Joseph L. Rice, III
               ---------

                                       8
<PAGE>

               and

               Debevoise & Plimpton
               875 Third Avenue
               New York, New York  10022
               Attention:  Franci J. Blassberg, Esq.
               ---------

The Fund also shall be given a copy of any notice or other communication between
the Purchaser and the Company under this Agreement at its address as set forth
above.

     (b) Binding Effect; Benefits. This Agreement shall be binding upon the
         ------------------------
parties to this Agreement and their respective successors and assigns and shall
inure to the benefit of the parties to the Agreement, the Fund and their
respective successors and assigns. Except as provided in Section 6, nothing in
this Agreement, express or implied, is intended or shall be construed to give
any person other than the parties to this Agreement, the Fund or their
respective successors or assigns any legal or equitable right, remedy or claim
under or in respect of any agreement or any provision contained herein.

     (c) Waiver; Amendment.
         -----------------

     (i) Waiver. Any party hereto or beneficiary hereof may by written notice
         ------
to the other parties (A) extend the time for the performance of any of the
obligations or other actions of the other parties under this Agreement, (B)
waive compliance with any of the conditions or covenants of the other parties
contained in this Agreement and (C) waive or modify performance of any of the
obligations of the other parties under this Agreement, provided that any waiver
of the provision of Section 6 must be consented to in writing by the Fund.
Except as provided in the preceding sentence, no action taken pursuant to this
Agreement, including, without limitation, any investigation by or on behalf of
any party or beneficiary shall be deemed to constitute a waiver by the party or
beneficiary taking such action of compliance with any representations,
warranties, covenants or agreements contained herein. The waiver by any party
hereto or beneficiary hereof of a breach of any provision of this Agreement
shall not operate or be construed as a waiver of any preceding or succeeding
breach and no failure by a party to exercise any right or privilege hereunder
shall be deemed a waiver of such party's or beneficiary's rights or privileges
hereunder or shall be deemed a waiver of such party's or beneficiary's rights to
exercise the same at any subsequent time or times hereunder.

     (ii) Amendment. This Agreement may not be amended, modified or supplemented
          ---------
orally, but only by a written instrument executed by the Purchaser and the
Company, and (in the case of any amendment, modification or supple-

                                       9
<PAGE>

ment to or affecting Section 6 hereof, or that adversely affects the rights of
the Fund hereunder) consented to by the Fund in writing.

     (d) Entire Agreement. This Agreement is the entire agreement of the
         ----------------
parties with respect to the subject matter hereof and supersedes all other prior
agreements, understandings, documents, statements, representations and
warranties, oral or written, express or implied, between the parties hereto and
their respective affiliates, representatives and agents in respect of the
subject matter hereof.

     (e) Assignability. Neither this Agreement nor any right, remedy, obligation
         -------------
or liability arising hereunder or by reason hereof shall be assignable by the
Company or the Purchaser without the prior written consent of the other parties
and the Fund. The Fund may assign from time to time all or any portion of its
rights under Section 6 hereof to one or more persons or other entities
designated by it.

     (f) Applicable Law. This Agreement shall be construed in accordance with
         --------------
and governed by the laws of the State of New York, without giving effect to the
conflicts of laws rules thereof to the extent such rules would require or permit
the application of the laws of another jurisdiction, except to the extent that
the corporate law of the jurisdiction of incorporation of the Company
specifically and mandatorily applies.

     (g) Section and Other Headings, etc. The section and other headings
         -------------------------------
contained in this Agreement are for reference purposes only and shall not affect
the meaning or interpretation of this Agreement.

     (h) Counterparts. This Agreement may be executed in any number of
         ------------
counterparts, each of which shall be deemed to be an original and all of which
together shall constitute one and the same instrument.

     (i) Delegation by the Board. All of the powers, duties and
         -----------------------
responsibilities of the Board specified in this Agreement may, to the full
extent permitted by applicable law, be exercised and performed by any duly
constituted committee thereof to the extent authorized by the Board to exercise
and perform such powers, duties and responsibilities.

                                       10
<PAGE>

     IN WITNESS WHEREOF, the Company and the Purchaser have executed this
Agreement as of the date first above written.

                              DYNATECH CORPORATION

                              By:
                                  --------------------------------
                                  Name:
                                  Title:

                              THE PURCHASER

                              By:
                                  --------------------------------
                                  Name:

                              Address of the Purchaser:

                              ------------------------------------

                              ------------------------------------

                              ------------------------------------

Total Number of Shares
of Common Stock to be
Purchased:

----------------------

Cash Purchase Price:

$
 ---------------------

                                       11<PAGE>
                                                                  EXHIBIT 10.116

                               LICENSE AGREEMENT
                                    BETWEEN
         INTERNEURON PHARMACEUTICALS, INC.  AND WARNER-LAMBERT COMPANY

     THIS LICENSE AGREEMENT (the "AGREEMENT") is made effective as of  December
23, 1999 (the "Effective Date") by and between INTERNEURON PHARMACEUTICALS,
INC., a Delaware corporation having its principal place of business at 99 Hayden
Avenue, Suite 200, Lexington, MA 02421-7966 ("INTERNEURON"), and WARNER-LAMBERT
COMPANY, a Delaware corporation having its principal place of business at 201
Tabor Road, Morris Plains, New Jersey  07950 ("WARNER").  Interneuron and Warner
may be referred to herein individually as a "Party" and collectively as the
"Parties".

                                    RECITALS

     A.  Warner is a global company devoted, among other businesses, to
         discovering, developing, manufacturing and marketing human
         pharmaceutical products.

     B.  Interneuron is engaged in the development of novel pharmaceuticals for
         central nervous system indications and has licensed from Rhone-Poulenc
         Rorer, S.A. ("RPR") certain rights to the Compound pursuant to the
         terms of that certain License Agreement dated February 18, 1994 by and
         between Interneuron and RPR (the "Interneuron-RPR License Agreement").

     C.  Interneuron desires to license to Warner and Warner desires to license
         from Interneuron all of Interneuron's right, title and interest in and
         to all intellectual property rights owned, licensed by or otherwise
         controlled by Interneuron relating to the Compound.

     THEREFORE, for good and valuable consideration, the receipt and sufficiency
of which is hereby acknowledged, the Parties hereby agree as follows:

                                   ARTICLE 1

                                  DEFINITIONS

     The following terms shall have the following meanings as used in this
Agreement:

     "AFFILIATE" shall mean, with respect to a Party, any other business entity
which directly or indirectly controls, is controlled by, or is under common
control with, such Party. As used in this definition of "Affiliate", the term
"control" shall mean direct or indirect beneficial ownership of more than 50% of
the voting or income interest in such business entity.

     "COMMERCIALIZATION"  means the manufacturing, marketing, sale, supply,
import, export and distribution of Licensed Products.

<PAGE>

     "COMPOUND" MEANS (+)-2-(7-chloro-1,8-naphtyridin-2-yl)-3-(5-methyl-2-
oxohexyl) phthalimidine; (+)-2-(7-chloro-1,8-naphthyridin-2-yl)-2,3-dihydro-3-
(5-methyl-2-oxohyxyl)-1H-isoindol-1-one known as RP62955 or pagoclone, as
diagrammed on Exhibit A attached hereto and any pharmaceutically acceptable
salts, hydrates, solvates, amides, prodrugs and esters thereof.

     "CONTROL" means possession of the ability to grant a license or
sublicense as provided for herein without violating the terms of any agreement
or other arrangement with any Third Party.

     "DEVELOPMENT" means those activities undertaken with respect to a
Compound or Licensed Product which are devoted to the exploration of a potential
pharmaceutical product in human clinical trials and/or the conduct of any other
activities or studies, including, without limitation, pre-clinical testing,
toxicology, formulation, bulk production, fill/finish, manufacturing process
development, test method development and validation, technology transfer,
stability testing, process validation, manufacturing and quality assurance
technical support, clinical trials, regulatory affairs and other activities
directed toward Regulatory Approval of such Compound or Licensed Product.

     "DRUG APPROVAL APPLICATION" means an application for Regulatory Approval
required before commercial sale or use of a Licensed Product as a pharmaceutical
product in a regulatory jurisdiction.

     "EFFECTIVE DATE" shall mean the date first set forth above.

     "EUROPE" means the countries of France, Germany, Italy, Spain and the
United Kingdom.

     "FDA" means the United States Food and Drug Administration or any
successor thereto.

     "FIRST COMMERCIAL SALE" shall mean, with respect to any Licensed Product,
the first sale to a Third Party for end use or consumption of such Licensed
Product in a country after receipt of Regulatory Approval in such country or,
where Regulatory Approval is not required, the first sale in that country in
connection with the nationwide introduction of such Licensed Product in that
country by Warner, its Affiliates or sublicensees.

    "FOREIGN ROYALTY YEAR" shall mean each successive twelve (12) month period
commencing with the first day of the first month in which occurs the First
Commercial Sale in any country outside the United States.

     "IND" means an Investigational New Drug Application as defined in the
United States Food, Drug and Cosmetic Act and applicable regulations promulgated
thereunder by the FDA or the equivalent application to the equivalent agency in
any other regulatory jurisdiction, the filing of which is necessary to commence
clinical testing of pharmaceutical products in humans.

<PAGE>

    "INTERNEURON PATENT RIGHTS" means any and all United States and foreign
patents (including all provisionals, reissues, extensions, substitutions,
confirmations, re-registrations, re-examinations, revalidations and patents of
addition) and patent applications (including, without limitation, all
continuations, continuations-in-part, and divisions thereof), the subject matter
of which relates to any aspect of the manufacture, use, lease or sale of the
Compound or any Licensed Product or intermediates used in the manufacture of the
Compound or any Licensed Product, including without limitation, the RPR Patents
and the patents listed on Exhibit B which is attached hereto and incorporated
herein by reference.

    "KNOW-HOW" means all proprietary information and technology, including
trade secret information, developments, discoveries, methods, techniques,
formulations, clinical and pre-clinical data, toxicology, stability data,
pharmacology data, and other information owned or Controlled by Interneuron,
whether or not patentable, relating to the Compound or any Licensed Product or
any improvements thereof, presently known to Interneuron or generated by or on
behalf of Interneuron, including such rights which Interneuron may have to
information developed by third parties relating to capsule formulation for use
with the Compound or any Licensed Product and such know how as Interneuron
licensed from RPR.

    "LICENSED PRODUCT" means all finished pharmaceutical formulations
containing the Compound in any dosage form for human use.

    "NDA" shall mean a New Drug Application filed with FDA, or the equivalent
application filed in Europe.

    "NET SALES" means the gross amount invoiced to Third Parties by any
Party, its Affiliates and its permitted sublicensees for all Licensed Products
sold after deduction for the following items (i) trade, quantity and cash
discounts or rebates actually allowed, paid or taken; (ii) credits, rebates,
charge-back rebates, reimbursements or similar payments actually granted or
given to wholesalers and other distributors, buying groups, health care
insurance carriers, governmental agencies and other institutions; (iii) credits
or allowances actually granted or given for rejection or return of such Licensed
Product previously sold; (iv) any tax, tariff, duty or other governmental charge
(other than an income tax) levied on the sale, transportation or delivery of
Licensed Product and actually borne by the seller thereof; (v) payments or
rebates actually paid in connection with state or federal Medicare, Medicaid or
similar programs; (vi) any charge for freight or insurance actually borne by the
seller thereof; and (vii) actual writeoffs or bad debts consistent with Warner's
past internal financial policies.

    "PHASE II CLINICAL TRIAL" means a clinical trial designed to establish the
safety and biological activity of a pharmaceutical product for its intended use.

    "PHASE III CLINICAL TRIALS" means those trials on sufficient numbers of
patients that are designed to establish that a pharmaceutical product is safe
and efficacious for its intended use, and to define warnings, precautions and
adverse reactions that are associated with the pharmaceutical product in the
dosage range to be prescribed, and supporting Regulatory Approval of such
pharmaceutical product or label expansion of such pharmaceutical product.

<PAGE>

    "REGULATORY APPROVAL" means all approvals (including pricing and
reimbursement approvals required for marketing authorization), product and/or
establishment licenses, registrations or authorizations of all regional,
federal, state or local regulatory agency, department, bureau or other
governmental entity, necessary for the manufacture, use, storage, import,
export, transport and sale of any Licensed Product in a regulatory jurisdiction.

    "RPR PATENTS" shall have the meaning set forth in Section 6.1.

    "THIRD PARTY" means any entity other than Interneuron or Warner or their
Affiliates.

    "U.S. ROYALTY YEAR" shall mean each successive twelve (12) month period
commencing with the first day of the first month in which occurs the First
Commercial Sale in the United States.

    "VALID CLAIM" shall mean any claim issued in an unexpired patent which has
not been held unenforceable, unpatentable or invalid by a decision of a court or
other governmental agency of competent jurisdiction following exhaustion of all
possible appeal processes, and which has not been admitted to be invalid or
unenforceable through reissue, reexamination or disclaimer and has not been
terminated for failure to pay maintenance fees.

                                   ARTICLE 2

                                 LICENSE GRANT

     2.1  LICENSES TO WARNER.

     (A)  Subject to the terms of this Agreement, Interneuron hereby grants to
          Warner an exclusive (even as to Interneuron), worldwide, royalty-
          bearing license under the Interneuron Patent Rights and Interneuron
          Know-How to develop, make, have made, use, sell, offer for sale, have
          sold and import the Compound and any Licensed Products for all
          indications.

     (B)  Warner shall have the first right to initiate and prosecute any
          action, claim, complaint, lawsuit or other proceedings against RPR,
          its Affiliates, agents, representatives, employees, officers or
          directors or any successor in interest to any of the foregoing,
          relating to the matters set forth in the following sentence that
          Interneuron may have at law or in equity (a "Claim") in any court of
          competent jurisdiction, in any country in the world, in Interneuron's
          name, and collect any monetary damages awarded or settlement payments
          made, or enforce any other decision, judgment or decree arising from
          such Claim. Warner shall only have the first right to bring a Claim
          for breach, default or threatened breach or default of any of the
          terms, conditions, obligations and/or representations of RPR under the
          Interneuron-RPR License Agreement or any breach or threatened breach
          of any

<PAGE>

          obligation of RPR to Interneuron relating to such Interneuron-RPR
          License Agreement, to the extent such breach, default or threatened
          breach or default arises out of or relates to acts or omissions of RPR
          regarding RPR's commercializing, marketing, selling, promoting,
          distributing, manufacturing, using, exporting or importing the
          Compound or any Licensed Product. In the event Warner elects not to
          exercise such right, Warner shall promptly notify Interneuron and
          Interneuron shall then have the right to initiate and prosecute any
          such Claim. Interneuron shall promptly inform Warner in writing of any
          breach or threatened breach by RPR of the Interneuron-RPR License
          Agreement of which it becomes aware.

     (C)  Any recovery obtained by Warner or Interneuron under Section 2.1 (b)
          shall be shared as follows:

          (i)   the Party that initiated and prosecuted the Claim shall recoup
                all of its costs and expenses incurred in connection with the
                Claim, whether by settlement or otherwise;

          (ii)  the other Party then shall, to the extent possible, recover its
                costs and expenses incurred in connection with the Claim;

          (iii)  if Interneuron initiated and prosecuted the Claim, the amount
                 of any recovery received by Interneuron and remaining after the
                 application of Sections 2.1(c)(i) - (ii) shall be retained by
                 Interneuron; and

          (iv)   if Warner initiated and prosecuted the Claim, the amount of any
                 recovery received by Warner and remaining after the application
                 of Sections 2.1(c)(i) - (ii) shall be retained by Warner except
                 that Interneuron shall receive a portion equivalent to the
                 payments they would have received on such remaining amount if
                 such amount were deemed Net Sales.

     2.2  SUBLICENSING.   Subject to the terms of the Interneuron-RPR License
Agreement, Warner shall have an unrestricted right to grant to Affiliates and
non-Affiliates sublicenses of any and all rights licensed to Warner by
Interneuron under this Agreement and Warner shall have an unrestricted right to
grant sublicenses to Third Parties to assist Warner in performing any of its
obligations or to exercise any of its rights under this Agreement. At the time
it provides each report required under Section 4.3(e), or upon Interneuron's
prior written request (which request may only be made up to two times in any
twelve month period), Warner shall notify Interneuron of each sublicense granted
in each country in the US, Japan and Europe to permit a Third Party to promote
or market any Licensed Products.  Any sublicense permitted under this Agreement
to be granted shall be subject to the terms and conditions of the license
itself, and Warner shall be responsible for and shall guarantee the performance
by the sublicensee of such obligations.

<PAGE>

     No such sublicensee shall acquire any rights from or obligations on the
part of Interneuron, other than those that are specifically granted in this
Agreement, and each such sublicensee shall assume all obligations to Interneuron
required of Warner by this Agreement applicable to the sublicensed rights.

                                   ARTICLE 3

                   TRANSITION; DEVELOPMENT; COMMERCIALIZATION

     3.1 INFORMATION, KNOW-HOW AND MATERIALS. Within 30 days of the date hereof,
Interneuron shall deliver to Warner electronic, where available, and hard copies
(or, upon Warner's request, originals) of all information, records and data, and
all Know-How which it owns or Controls and which are necessary or useful for the
continued research, Development and Commercialization of the Compound and the
Licensed Products, and Interneuron shall forward to Warner all supplies of the
Compound and the Licensed Products which it owns or controls, and samples of all
other chemical and biological materials necessary for the continued research,
Development and Commercialization of the Compound and the Licensed Products.

     3.2 REGULATORY FILINGS, APPROVALS AND APPLICATIONS. Within 10 days of the
date hereof, Interneuron shall transfer to Warner all regulatory filings,
approvals and applications relating to the Compound or the Licensed Products,
including all IND's and all Regulatory Approvals and all related documentation
and information. Interneuron shall notify the FDA that all such IND's and all
responsibilities related thereto, have been transferred to Warner.

     3.3 REGULATORY MATTERS. After the Effective Date, Warner shall own, control
and retain primary legal responsibility for the preparation, filing and
prosecution of all filings and regulatory applications required to obtain
Regulatory Approval in each country. Warner shall have sole responsibility for,
bear all costs and expenses associated with and make all decisions with respect
to any recall, withdrawal or seizure of the Licensed Product. Any Licensed
Product returned to Interneuron shall be shipped to Warner's nearest facility,
with any reasonable or authorized shipping or other documented direct cost to be
paid by Warner. Interneuron shall provide Warner with immediate notice of all
adverse events of which Interneuron becomes aware which arise from all clinical
trials of the Compound and the Licensed Products, conducted by Interneuron or
its representatives.

     3.4  AGREEMENTS.  Attached hereto as Exhibit C is a list of all contracts,
agreements and other arrangements (other than the Interneuron-RPR License
Agreement which is attached as Exhibit D) between Interneuron and any and all
Third Parties relating to the research, Development or Commercialization of the
Compound and the Licensed Products. Interneuron shall promptly (and in no event
later than 5 days after a request from Warner) assign to Warner the contracts
and agreements listed in Exhibit C which Warner shall specifically request, and
Interneuron shall terminate such other contracts, agreements or other
arrangements, as Warner shall request.  Without Warner's prior written consent,
Interneuron shall not modify, amend or

<PAGE>

terminate the agreements listed on Exhibit C and Interneuron shall not enter
into any other agreements regarding the Compound or the Licensed Products.

     3.5 MANUFACTURING DEVELOPMENT; COMMERCIALIZATION. After the Effective Date,
Warner shall control, in its discretion, and shall be solely responsible for
Development, Manufacture and Commercialization of the Compound and the Licensed
Products conducted or performed after the date hereof.

     3.6 ALL OTHER ACTS NECESSARY OR USEFUL. Interneuron shall take such other
actions and execute such other instruments, assignments and documents as may be
reasonably necessary or useful to effect the transfer of rights hereunder to
Warner. Interneuron shall further render such assistance as Warner shall
reasonably request in the transfer of Know-How relating to the Compound and the
Licensed Products.

     3.7 DILIGENCE; DEVELOPMENT AND COMMERCIALIZATION.

         (A) After the Effective Date, Warner will be responsible for conducting
and fully funding all Development, regulatory filings, and Commercialization of
the Licensed Products. Warner shall only be obligated to develop or
commercialize the Licensed Products using not less than those efforts Warner
applies with respect to its other drug candidates and pharmaceutical products of
a comparable stage of development and commercial potential. Warner shall not be
obligated to pursue Development or Commercialization in any specific
jurisdiction. Interneuron's only remedy in the event Warner fails to fulfill the
obligation set forth in the second sentence of this Section 3.7 shall be to
terminate this License Agreement under Section 8.3 and require Warner to provide
Interneuron with all samples of the Licensed Product. Warner shall comply with
all applicable laws and regulations in the Commercialization of Licensed
Products. No more than twice per calendar year, Interneuron may request a
meeting with Warner to discuss a summary of the progress and results of Warner's
Development and Commercialization at dates and locations to be mutually agreed
to. Any disclosures of such progress and results shall be deemed Confidential
Information of Warner. Warner shall also notify Interneuron as soon as
reasonably practicable upon the achievement of milestones listed in 4.1(a)
below, the receipt of Regulatory Approvals in the United States, Japan and
Europe, and the date of First Commercial Sale in the United States, Japan and
Europe.

         (B)  In addition to and not in lieu of the obligations of Warner under
the second sentence of Section 3.7(a), Warner shall:

     1.  Either dose the first patient in a Phase III Clinical Trial for Panic
         Disorder by the 12 month anniversary of the date this Agreement is
         fully signed by authorized representatives of each Party or pay to
         Interneuron the amount set forth in Section 4.2(a)(1) (which payment
         shall be deemed to be in lieu of the obligation to make such payment
         under Section 4.2(a)); and

     2.  Either dose the first patient in a Phase II Clinical Trial for General
         Anxiety Disorder by the 12 month anniversary of the date this Agreement
         is fully signed by authorized representatives of each party, or pay to
         Interneuron

<PAGE>

         $* dollars by such twelve month anniversary (which payment shall be
         credited against any milestone payments due under Section 4.2(a)(2));
         and

     3.  Either dose the first patient in a Phase III Clinical Trial for General
         Anxiety Disorder by the 24 month anniversary of the date this Agreement
         is fully signed by authorized representatives of each party, or pay to
         Interneuron the amount set forth in Section 4.2(a)(2) (which payment
         shall be deemed to be in lieu of the obligation to make such payment
         under Section 4.2(a)) less any amounts paid under Section 3.7(b)(2)
         above.

     In the event that Warner fails to fulfill its obligations set forth in
Section 3.7(b)(1), 3.7(b)(2) or 3.7(b)(3), Interneuron shall have the right to
terminate this License Agreement and the provisions of Section 8.5 of this
Agreement shall apply to such termination.

         (C) Notwithstanding the foregoing, Interneuron shall not have the right
to terminate this Agreement under Section 3.7(b) in the event Warner's failure
to fulfill its obligations under Section 3.7(b)(1) through (3) is due to any of
the following circumstances (except, in the case of (c)(1) or (c)(2), if such
circumstances are directly caused by any negligent act or omission of Warner):

     1.  Unavailability of drug supplies needed to conduct the applicable
         clinical trial, including, without limitation, as a result of failure
         of stability or lack of a satisfactory formulation;

     2.  An inability to conduct the applicable clinical trial due to action on
         the part of the FDA or any foreign equivalent, including, without
         limitation, the placement of a clinical hold on such clinical trial;

     3.  The conduct of such clinical trial would violate any applicable
         laws, rules or regulations;

     4.  A good faith determination on the part of Warner that the Licensed
         Product which is intended to be studied in the applicable clinical
         trial is not safe or efficacious in its then current formulation or
         dosage form or dose level, provided Warner is engaged in good faith
         efforts to pursue development of a Licensed Product;

     5.  Any circumstances described in Section 10.2.

                       *CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

                                   ARTICLE 4

                               PAYMENT PROVISIONS

     4.1       LICENSE FEE.  In consideration for the license granted hereunder
and to reimburse Interneuron for development costs of the Compound and the
Licensed Products, Warner shall pay Interneuron, within 10 days of the Effective
Date,  the non-refundable and noncreditable sum of Thirteen Million Seven
Hundred Fifty Thousand ($13,750,000) Dollars.

     4.2       MILESTONE PAYMENTS.

   (A)  MILESTONE AMOUNTS. Warner shall notify Interneuron upon the achievement
of each of the following milestones, and Warner shall make the following
milestone payments to Interneuron within thirty (30) days after the first
achievement of each of the following milestones:

   1.  Upon dosing of the first patient in a Phase III Clinical Trial
       for Panic Disorder                                                $    *
   2.  Upon dosing of the first patient in a Phase III Clinical Trial
       for General Anxiety Disorder                                      $    *
   3.  Successful completion of toxicology studies followed by
       a decision of Warner to continue Development of
       the Licensed Product                                              $    *
   4.  On acceptance for filing by the FDA of an NDA for
       Panic Disorder                                                    $    *
   5.  On acceptance for filing by the FDA of an NDA for
       General Anxiety Disorder                                          $    *
   6.  On Regulatory Approval by the FDA for Panic Disorder              $    *
   7.  On Regulatory Approval by the FDA for General Anxiety Disorder    $    *

                       *CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

   8.  On acceptance for filing of an NDA in Europe
       for Panic Disorder                                                $     *
   9.  On acceptance for filing of an NDA in Europe for
       General Anxiety Disorder                                          $     *
  10.  On Regulatory Approval in Europe for Panic Disorder               $     *
  11.  On Regulatory Approval in  Europe for
       General Anxiety Disorder                                          $     *
  12.  On acceptance for filing with Koseshio in Japan for the first
       indication  for which such filing is made                         $     *
  13.  On Regulatory Approval in Japan of the first Licensed Product for
       the first indication for which Regulatory Approval is obtained    $     *
  14.  Upon acceptance for filing by the FDA of an NDA for an SR form of
       the Licensed Product                                              $     *
  15.  Upon Regulatory Approval by the FDA for an SR form of
       the Licensed Product                                              $     *
  16.  Upon Regulatory Approval by the FDA for each of the first three
       additional indications for which an NDA is required to be filed
       for the Licensed Product                                          $     *
  17.  Upon Regulatory Approval in Europe for each of the first three
       additional indications for which an NDA is required to be filed
       for the Licensed Product                                          $     *

For convenience of reference, each of the events listed in Section 4.2 shall be
referred to as a "Trigger Event".  For Trigger Event numbers 8, 9, 10, 11 and
17, in the event the applicable acceptance for filing or approval is granted in
less than all of the countries listed in the definition of "Europe", Warner
shall pay an amount equal to one-fifth of the applicable milestone payment for
such Trigger Event, multiplied by the number of countries in which such
acceptance for filing or approval is granted.

*CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

     (B)  ONE MILESTONE PER PRODUCT.  The milestone payments received by
Interneuron under Section 4.2(a) shall be non-refundable and noncreditable.
Except for the milestones payable on achievement of Trigger Event numbers 16 and
17, each milestone payment referred to in Section 4.2(a) shall be made only
once, regardless of whether additional indications or additional formulations of
a Licensed Product are developed or commercialized.

     4.3  ROYALTY PAYMENTS ON LICENSED PRODUCTS.

          (A)  ROYALTY AMOUNT AND TERM.  Warner shall pay Interneuron a royalty
payment on Net Sales according to the following rates during the "Royalty Term".
The "Royalty Term" shall be applied on a country by country basis and shall
mean, in any country, the period of time commencing on the First Commercial Sale
of Licensed Product and ending upon the later of (a) 10 years from the date of
such First Commercial Sale or (b) the expiration of the last to expire Valid
Claim in the Interneuron Patent Rights, in such country, which is necessary, to
make, use or sell  Licensed Product in such country; provided that, if any such
Valid Claim exists after such 10 year period, and if another product containing
the same active ingredient is sold following the 10 year period from the date of
the First Commercial Sale in such country without Warner's permission and
without infringing any such Valid Claim, then the royalty obligation with
respect to such country shall be terminated as of the date of first commercial
sale of such other product in such country.

     (i) Royalties due on sales in the United States:

                              Annual Net Sales (in millions)
     Royalty Percentage       in each U.S. Royalty Year
     ------------------       -------------------------

     *%                       up to $*
     *%                       in excess of $* and up to $*
     *%                       in excess of $*

     (ii) Royalties due on sales outside the United States (other than France):

                              Annual Net Sales (in millions)
     Royalty Percentage       in each Foreign Royalty Year (excluding France)
     ------------------       -----------------------------------------------

     *%                       up to $*
     *%                       in excess of $* and up to $*
     *%                       in excess of $* and up to $*
     *%                       in excess of $*

*CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

By way of example, the first $* of Net Sales in any U.S. Royalty Year shall only
be subject to a royalty rate of *% regardless of whether Net Sales in the United
States for such U.S. Royalty Year exceed $*.  Similarly, the first $* of total
Net Sales in all countries other than France and the  United States in any
Foreign Royalty Year shall only be subject to a royalty of * percent (*%),
regardless of whether Net Sales outside the United States (excluding France) for
such Foreign Royalty Year exceed $*. Warner shall not be obligated to pay any
royalties for Net Sales in France.

          (B) ROYALTIES OWED TO THIRD PARTIES. Warner will pay any and all
royalties owed to Third Parties by Warner in respect of the manufacture, use or
sale of Licensed Products.  Interneuron will pay any and all royalties owed to
Third Parties by Interneuron (including, without limitation, pursuant to the
Interneuron-RPR License Agreement) in respect of the manufacture, use or sale of
Licensed Products.

          (C) ROYALTY REDUCTION IN CASE OF ROYALTIES OWED TO THIRD PARTIES.
Warner may deduct from any royalties owed to Interneuron under this Agreement,
fifty percent (50%) of royalties required to be paid by Warner to Third Parties
which are necessary for the sales of such Licensed Product and which relate to
claims covering the composition of matter of the Compound or its manufacture or
use.

          (D) CURRENCY OF PAYMENT. All payments to be made under this Agreement
shall be made in United States dollars in the United States to a bank account
designated by Interneuron.  Royalties earned shall first be determined in the
currency of the country in which they are earned and then converted to its
equivalent in United States currency. Such conversion shall be based on the
average buying rates of exchange for the currencies involved into the currency
of the United States quoted by Citibank (or its successor in interest) in New
York, New York at the close of business on each business day of the quarterly
period in which the royalties were earned.

          (E) PAYMENT AND REPORTING. The royalties due under this Section shall
be paid quarterly, within thirty (30) days following each calendar quarter which
such royalties are earned, or earlier if practical. With each such quarterly
payment, Warner shall furnish Interneuron a royalty statement, setting forth, on
a country-by-country basis, the total number of units of each royalty-bearing
Licensed Product made, used and/or sold hereunder for the quarterly period for
which the royalties are due and a calculation of Net Sales for such Licensed
Product.  In addition, Warner shall furnish such a royalty statement on a
country-by-country basis (except France) for the first quarter during which
Warner makes sales of Licensed Product for which no royalty payment in respect
of such country is due hereunder, and shall state the basis for such sales then
being free of royalty obligations hereunder.  Warner shall thereafter have no
further obligation to report the number of units or Net Sales of such Licensed
Product made, used and/or sold in such country.

*CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

          (F) RECORDS. Warner shall keep accurate books and accounts of record
in connection with the manufacture, use and/or sale by or for it of the Licensed
Products hereunder in sufficient detail to permit accurate determination of all
figures necessary for calculation and verification of royalty obligations set
forth in this Article 4. Such records shall be maintained for a period of three
(3) years from the end of each U.S. Royalty Year and Foreign Royalty Year in
which sales occurred.  Interneuron, at its expense, through a nationally
recognized certified public accounting firm, shall have the right to access such
books and records for the sole purpose of verifying the royalty statements; such
access shall be conducted after reasonable prior notice by Interneuron to Warner
and conducted during Warner's ordinary business hours and shall not be more
frequent than once during each calendar year. Said certified public accountant
shall agree not disclose to Interneuron or any other party any information
except that which should properly be contained in a royalty report required
under this Agreement.  If such certified public accountant concludes that
additional royalties were owed during such period, Warner shall pay the
additional royalties within ten (10) days of the date Interneuron delivers to
Warner such accounting firm's written report so concluding.  In the event such
certified public accountant concludes that amounts were overpaid by Warner
during such period, Interneuron shall reimburse Warner the amount of such
overpayment within ten (10) days of receipt of such certified public
accountant's written report.  The fees charged by such certified public
accountant shall be paid by Interneuron; provided, however, that if an error in
favor of Interneuron in the payment of royalties of more than ten percent (10%)
of the royalties due hereunder for the period being reviewed is discovered, then
the fees and expenses of the certified public accountant shall be reimbursed by
Warner.

          (G) TAXES WITHHELD. Any income or other tax that one Party
hereunder, its Affiliates or sublicensees is required to withhold (the
"Withholding Party") and pay on behalf of the other Party hereunder (the
"Withheld Party") with respect to the royalties payable under this Agreement
shall be deducted from and offset against said royalties prior to remittance to
the Withheld Party; provided, however, that in regard to any tax so deducted,
the Withholding Party shall give or cause to be given to the Withheld Party such
assistance as may reasonably be necessary to enable the Withheld Party to claim
exemption therefrom or credit therefor, and in each case shall furnish the
Withheld Party proper evidence of the taxes paid on its behalf.

          (H) COMPUTATION OF ROYALTIES. All sales of Licensed Products between
any Party and any of its Affiliates and sublicensees shall be disregarded for
purposes of computing royalties under this Article 4, but in such instances
royalties shall be payable only upon sales to unlicensed Third Parties. Nothing
herein contained shall obligate any Party to pay the other Party more than one
royalty on any unit of any Licensed Product.

<PAGE>

          (I) LICENSES TO AFFILIATES.  Interneuron shall, at Warner's request,
sign license and/or royalty agreements directly with Warner's Affiliates and
sublicensees in those situations where such agreements would not decrease the
amount of royalties or milestones which would be owed hereunder. Such agreements
shall contain the same language as contained herein with appropriate changes in
parties and territory. No such license and/or royalty agreement will relieve
Warner or Interneuron, as the case may be, of its obligations hereunder, and
such Party will guarantee the obligations of its Affiliate or sublicensee in any
such agreement. Royalties received directly from one Party's Affiliates and
sublicensees shall be credited towards such Party's royalty obligations
hereunder.

          (J) RESTRICTIONS ON PAYMENT. The obligation to pay royalties under
this Agreement shall be waived and excused to the extent that statutes, laws,
codes or governmental regulations in a particular country prevent such royalty
payments by the seller of Licensed Products; provided, however, that if legally
permissible, the seller of Licensed Products shall pay the royalties owed to the
other party hereto by depositing such amounts in a bank account in such country
that has been designated by the party owed such royalties.

                                   ARTICLE 5

                                CONFIDENTIALITY

     5.1  CONFIDENTIALITY.  Except as specifically permitted hereunder, each
Party hereby agrees to hold in confidence and not use on behalf of itself or
others the terms of this Agreement and all data, samples, technical and economic
information (including the economic terms hereof), commercialization, clinical
and research strategies and know-how which it obtained during the research or
development of the Compound or the Licensed Products or which it obtains from
the disclosing Party pursuant to the terms of this Agreement during the term of
this Agreement and for a period of five years thereafter (collectively the
"Confidential Information"), except that the term "Confidential Information"
shall not include:

          (I) information that is or becomes part of the public domain through
no fault of the receiving party or its Affiliates;

          (II) information that is obtained after the date hereof by one of the
Parties or one of its Affiliates from any Third Party which is lawfully in
possession of such Confidential Information and not in violation of any
contractual or legal obligation to the other Party or its Affiliates with
respect to such Confidential Information;

          (III) information independently developed by a Party or its
Affiliates, without application of the other Party's Confidential Information;

<PAGE>

          (IV) information that is known to one of the Parties or one or more of
its Affiliates prior to disclosure by the other Party or its Affiliates, as
evidenced by such first Party's written records;

          (V)  information that is necessary to be disclosed to any governmental
authorities or pursuant to any regulatory filings (other than NDAs or INDs),
provided that in such case the Party notifies the other Party reasonably in
advance of such disclosure and cooperates with such Party to minimize the scope
or content of such disclosure, provided however that Interneuron may disclose
and file this Agreement with the SEC, if required by federal law, after it
redacts information from such disclosure to the full extent permitted by law; or

          (VI) information required to be disclosed to RPR pursuant to the terms
of the Interneuron-RPR License Agreement or any agreements between RPR and
Warner relating to development of the Compound or Licensed Product or
commercialization of the Compound or the Licensed Product for sale in France.

The obligations of this Section 5.1 shall survive the expiration or termination
of this Agreement.

     5.2  PUBLICITY. Notwithstanding the foregoing Section 5.1,Warner shall be
free to issue all publicity, press releases and other announcements and
publications relating to this Agreement and the research, Development and
Commercialization of the Compound and the Licensed Products (including
information supplied by Interneuron) as it shall deem fit.  Interneuron shall
not issue any publicity, press releases and other announcements relating to this
Agreement or the transactions contemplated hereby without the prior approval of
Warner, which approval shall not be unreasonably withheld or delayed; provided
however that Interneuron may issue any public statements only to the extent
required to be disclosed pursuant to applicable laws, rules and regulations and
then, only to the extent Warner is given a copy of such disclosure at least 2
business days prior to such disclosure.  Warner agrees to furnish to Interneuron
copies of any such publicity, press releases and any announcements at the time
Warner releases such publicity or such announcements to the public or as soon
thereafter as is reasonably practical.

                                   ARTICLE 6

              OWNERSHIP OF INTELLECTUAL PROPERTY AND PATENT RIGHTS

     6.1   PROTECTION OF RPR PATENT RIGHTS. Interneuron shall continue to
be responsible for reimbursing RPR for all costs associated with the prosecution
and maintenance of all patent and patent applications referenced in the first
sentence of Section 6.1 of the

<PAGE>

Interneuron-RPR License Agreement (the "RPR Patents"). Interneuron shall provide
all information relating to the status and progress of the prosecution and
maintenance of the RPR Patents, and copies of all relevant materials, which
Interneuron receives from RPR as soon as Interneuron receives such information
and materials from RPR. Interneuron shall further instruct RPR to provide such
information and materials directly to Warner, and upon Warner's request, shall
obtain from RPR all documents and other information that Interneuron is entitled
to obtain under the Interneuron-RPR License Agreement. In the event RPR elects
or has elected not to file, prosecute or maintain in any jurisdiction, patents
or patent applications contained within the RPR Patents, and Interneuron has the
right to assume or has assumed such filing, prosecution or maintenance,
Interneuron shall immediately notify Warner and Warner shall have the right at
its option, in each such jurisdiction, to file, prosecute and maintain such
patents and patent applications in its own name and at its sole cost.

          6.2  PROTECTION OF INTERNEURON PATENT RIGHTS.  To the extent
Interneuron has filed or is prosecuting or maintaining any patents or patent
applications claiming inventions made by its employees, representatives, agents
or contractors or otherwise owned or licensed by Interneuron, relating to the
Compound or the Licensed Products (the "Interneuron Patents"), Interneuron shall
continue to file, prosecute and maintain the Interneuron Patents at its sole
cost. Interneuron shall keep Warner fully informed of all matters relating to
the filing, prosecution and maintenance of the Interneuron Patents. In the event
Interneuron fails to file, prosecute or maintain any Interneuron Patents in any
jurisdiction, Interneuron shall immediately notify Warner and Warner shall have
the right at its option and expense, in each such jurisdiction, to assume the
filing, prosecution and maintenance of such Interneuron Patents, and Interneuron
shall assign to Warner all of Interneuron's right, title and interest in and to
such Interneuron Patents.

          6.3  PROTECTION OF WARNER PATENT RIGHTS.  To the extent Warner or its
employees, representatives, agents or contractors makes an invention relating to
the Compound or the Licensed Patents, Warner shall own such invention and shall
have the sole right, at its option and expense, to file, prosecute and maintain
any patent application or patent claiming such invention (such patents and
patent applications are hereinafter referred to as the "Warner Patents").

          6.4  ENFORCEMENT RIGHTS.

          (a)  INFRINGEMENT BY THIRD PARTIES.  If any Interneuron Patent,
     Warner Patent or RPR Patent is infringed by a Third Party in connection
     with the manufacture, import, use, sale or offer for sale of a product
     competitive with the Licensed Product, the Party first having knowledge of
     such  infringement shall promptly notify the other in writing.  The notice
     shall set forth the facts of that infringement in reasonable detail.  The
     Party having the primary right, but not the obligation, to institute,
     prosecute and control any

<PAGE>

     action or proceeding with respect to such infringement (the "Enforcing
     Party") shall be Interneuron for infringement of Interneuron Patents, and
     Warner for infringement of Warner Patents or any RPR Patents for which
     Interneuron otherwise has the right to institute, prosecute or control any
     such action or proceeding under the terms of the Interneuron-RPR License
     Agreement. The non-Enforcing Party shall have the right at its own expense
     to participate in any action brought by the Enforcing Party and to be
     represented by counsel of its own choice. If the Enforcing Party fails to
     bring an action or proceeding within a period of ninety (90) days after
     written notice from the other Party, the other Party shall have the right
     at its own expense to bring and control any such action by counsel of its
     own choice, and the Enforcing Party shall have the right to participate in
     such action and be represented by counsel of its own choice and shall
     further reimburse the non-Enforcing Party for one-half of the non-Enforcing
     Party's costs and expenses in bringing such action or proceeding. If a
     Party brings any such action or proceeding hereunder, the other Party
     agrees to give the Enforcing Party reasonable assistance and authority to
     control, file and prosecute the suit as necessary. The costs and expenses
     of the Party bringing suit under this Section (including the internal costs
     and expenses specifically attributable to said suit) shall be reimbursed
     first out of any damages or other monetary awards recovered in favor of the
     Parties. Any remaining damages shall be provided to Warner and such amount
     (after payment of costs and expenses attributable to the suit) shall be
     deemed to be Net Sales in the applicable country for the year in which such
     amount is actually received by Warner.

          (b)  DEFENSE AND SETTLEMENT OF THIRD-PARTY CLAIMS AGAINST LICENSED
     PRODUCTS.   If a Third Party asserts that a patent or other right owned by
     it is infringed by the development, manufacture, import, use, sale or offer
     for sale of the Compound or the Licensed Products, the Party first
     obtaining knowledge of such a claim shall immediately provide the other
     Party notice of such claim and the related facts in reasonable detail.
     Warner shall be primarily responsible for controlling the defense of any
     such infringement claim and Interneuron shall reimburse Warner for 50% of
     all costs and expenses incurred in such defense.  Interneuron shall further
     pay 50% of all damages awarded or settlement payments made to such Third
     Party as a result of such claimed infringement. To the extent any such
     claim relates to an Interneuron Patent or RPR Patent, Interneuron shall
     have the right at its own expense to participate in such defense and to be
     represented in any such action by counsel of its selection at its sole
     discretion.

     6.5  TRADEMARKS.      All Licensed Products shall be sold worldwide under
trademarks selected by Warner and Warner shall have the sole right to control
all matters relating to such trademarks.

<PAGE>

                                   ARTICLE 7

                  REPRESENTATIONS AND WARRANTIES; EXCLUSIVITY

     7.1  REPRESENTATIONS AND WARRANTIES.

     (a)  PARTY REPRESENTATIONS AND WARRANTIES.    Each of the Parties hereby
represents and warrants to the other Party as follows:

          (i) This Agreement is a legal and valid obligation binding upon such
Party and enforceable in accordance with its terms.  The execution, delivery and
performance of the Agreement by such Party does not conflict with any agreement,
instrument or understanding, oral or written, to which it is a Party or by which
it is bound, nor violate any law or regulation of any court, governmental body
or administrative or other agency having jurisdiction over it.

          (ii) Such Party has not granted, and during the term of the Agreement
will not, grant any right to any Third Party which would conflict with the
rights granted to the other Party hereunder.

     (b)  INTERNEURON REPRESENTATIONS AND WARRANTIES.   Interneuron hereby
represents and warrants to Warner as follows:

          (i) In the course of the development of the Licensed Product,
     Interneuron has not used any employee or consultant that is debarred by the
     FDA or, to the best of Interneuron's knowledge, is the subject of debarment
     proceedings by the FDA.

          (ii) Interneuron is not aware of any results or adverse events in  its
     ongoing clinical trials of the Licensed Product which would lead it to
     believe that such Licensed Product is not a viable pharmaceutical product
     or that such clinical trials were or should have been terminated because
     such Licensed Product is unsafe or not efficacious.

          (iii)  Interneuron has provided Warner with full, complete and
     accurate disclosure of all relevant information and materials in
     Interneuron's possession relating to the current status of the research,
     development and commercialization of the Licensed Products and all such
     research, development and commercialization conducted by Interneuron has
     been performed in accordance with applicable laws, rules and regulations.

          (iv) Attached as Exhibit B is a true and complete list of all patents
     and patent applications included within the Interneuron Patent Rights. As
     of the Effective Date,  Interneuron is not aware that the practice of the
     Interneuron Patent Rights or the Know-How as contemplated by this Agreement
     will involve any infringement or constitute an unauthorized use of any
     patent, copyright, trade secret, proprietary information, license or right
     therein belonging to any Third Party.

<PAGE>

          (v) Interneuron is not aware of any interferences or oppositions or
     other matters pending or threatened against RPR or Interneuron before any
     court or administrative office or agency which affect the Interneuron
     Patent Rights or the Know-How.

          (vi) Each of the patent applications included in the Interneuron
     Patent Rights is currently pending and in good standing. As of the
     Effective Date, Interneuron is not aware of any prior art or any fact which
     causes it to conclude that any Interneuron Patent Rights are invalid or
     unenforceable.

          (vii)  Attached as Exhibit D is a true and complete copy of the
     Interneuron-RPR License Agreement, including all supplements thereto and
     modifications or amendments thereof.  Interneuron is not, and to the best
     of its knowledge, RPR is not, in default under or in breach of any terms or
     provisions of the Interneuron-RPR License Agreement and such agreement is
     in full force and effect as of the date hereof.  During the term of this
     Agreement, Interneuron shall not amend, modify, terminate or cause a
     default under the Interneuron-RPR License Agreement, or reject the
     Interneuron-RPR License Agreement pursuant to 11 U.S.C. (S) 365.

                                   ARTICLE 8

                              TERM AND TERMINATION

     8.1       RIGHT OF WARNER TO TERMINATE DEVELOPMENT.     Warner may at any
time terminate this Agreement by giving six (6) months advance written notice to
Interneuron.  If Warner terminates this Agreement after a Licensed Product has
received Regulatory Approval in any jurisdiction, Interneuron shall pay Warner
*% of Net Sales in each country on such Licensed Product for the Royalty Term.

     8.2       TERM.   This Agreement shall commence as of the Effective Date
and, unless sooner terminated as provided herein, shall continue in effect until
the earlier of (a) the date on which Warner or its Affiliates or sublicensees
are no longer researching, developing, marketing or selling a Licensed Product
in any country, (b) the expiration of the last to expire Royalty Term or (c) the
date this Agreement is terminated pursuant to the terms hereof.  A termination
of the Interneuron-RPR License Agreement, including a rejection pursuant to 11
U.S.C. (S) 365, shall be deemed to be a termination of this Agreement.

     *CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

     8.3       TERMINATION FOR MATERIAL BREACH.    Subject to the provisions of
this Section 8.3, if either Party (the "BREACHING PARTY") shall have committed a
material breach and such material breach shall remain uncured and shall be
continuing for a period of ninety (90) days following receipt of notice thereof
by the other Party of such breach (the "NON-BREACHING PARTY"), then, in addition
to any and all other rights and remedies that may be available, the Non-
Breaching Party shall have the right to terminate this Agreement effective upon
the expiration of such ninety (90) day period; provided, however that if the
material breach is capable of being cured but cannot be reasonably cured in such
ninety (90) day period, then the right to terminate this Agreement shall not
arise if the allegedly Breaching Party has (i) during such period of time
submitted a plan which, if successfully carried out, would be effective in
curing such breach, and has commenced its execution of such plan, and (ii)
diligently pursues such plan thereafter to a successful conclusion.  Any such
notice of alleged material breach by the Non-Breaching Party shall include a
reasonably detailed description of all relevant facts and circumstances
demonstrating, supporting and/or relating to each such alleged material breach
by the Breaching Party.  Actual termination of this Agreement pursuant to this
Section 8.3 shall only occur upon a separate written notice by the Non-Breaching
Party after the end of the cure period.  Notwithstanding the foregoing, if any
such breach relates solely to one or more Licensed Products, then the Non-
Breaching Party may only terminate this Agreement only to the extent it applies
to such Licensed Product or Licensed Products and this Agreement shall remain in
effect as it applies to all other Licensed Products.

     8.4       SURVIVING RIGHTS.   The rights and obligations set forth in this
Agreement shall extend beyond the term or termination of the Agreement only to
the extent expressly provided for herein, or the extent that the survival of
such rights or obligations are necessary to permit their complete fulfillment or
discharge.  Without limiting the foregoing, the Parties have identified various
rights and obligations which are understood to survive, as follows:

     In the event of expiration or termination of this Agreement pursuant to
Section 8, the provisions of Articles 5, 7 and 9 shall survive.

     8.5 ACCRUED RIGHTS, SURVIVING OBLIGATIONS.   Termination, relinquishment or
expiration of the Agreement for any reason shall be without prejudice to any
rights which shall have accrued to the benefit of either Party prior to such
termination, relinquishment or expiration, including damages arising from any
breach hereunder.  Such termination, relinquishment or expiration shall not
relieve either Party from obligations which are expressly indicated to survive
termination or expiration of the Agreement.  Subject to the royalty described in
Section 8.1, in the event of termination under this Article 8, Warner shall
promptly return to Interneuron any and all rights to the Compound and the
Licensed Products, including but not limited to Interneuron Patent Rights and
Know-How, and shall grant Interneuron a royalty-free, fully paid-up license to
the Warner Patents, Know-How and data relating thereto in Warner's possession or
control at the time of termination relating to the Compound or the Licensed
Products only to the extent necessary for Interneuron's Development and
Commercialization of the Compound and the Licensed Products and then only to the
extent used by Warner in its Development and Commercialization of the Compound
and the Licensed Products.

<PAGE>

                                   ARTICLE 9

                                INDEMNIFICATION

     9.1 INDEMNIFICATION FOR LICENSED PRODUCTS.

          (a) WARNER INDEMNIFICATION. Warner hereby agrees to indemnify, save,
     defend and hold Interneuron and its agents and employees and RPR harmless
     from and against any and all suits, claims, actions, or demands by a Third
     Party for damages, liabilities, expenses and/or loss, including reasonable
     legal expense and attorneys' fees (collectively, "LOSSES"), resulting
     directly from (i) the manufacture, use, development, handling, storage,
     marketing, sale or other disposition of the Compound or the Licensed
     Products by Warner, its Affiliates or sublicensees, or (ii) Warner's breach
     in any material respect of any of its representations, warranties or
     obligations set forth in this Agreement or Warner's negligence or willful
     misconduct; except to the extent such Losses result from the negligence or
     willful misconduct of Interneuron, its agents or employees or RPR, or to
     the extent Interneuron is obligated to indemnify Warner for such Losses as
     provided in Section 9.1(b),

          (b) INTERNEURON INDEMNIFICATION. Interneuron hereby agrees to
     indemnify, save, defend and hold Warner and its agents and employees
     harmless from and against any and all Losses resulting directly from (i)
     Interneuron's breach in any material respect of any of its representations,
     warranties or obligations set forth in this Agreement, (ii) Interneuron's
     negligence or willful misconduct or (iii) Interneuron's research,
     development, use, manufacture, handling, storage or other disposition of
     the Compound or the Licensed Products, except to the extent such Losses
     result from the negligence or willful misconduct of Warner, its agents or
     employees, or to the extent Warner is obligated to indemnify Interneuron
     for such Losses as provided in Section 9.1(a).

     9.2       NOTICE OF CLAIM.   In the event that a Party is seeking
indemnification under this Article 9, it shall inform the other Party of a claim
as soon as reasonably practicable after it receives notice of the claim, shall
permit the indemnifying Party to assume direction and control of the defense of
the claim (including the right to settle the claim solely for monetary
consideration), and shall cooperate as requested (at the expense of the
Indemnifying Party) in the defense and settlement of the claim.  The indemnified
Party shall not voluntarily make any payment or incur any expense in connection
with any claim or suit without the consent of the indemnifying Party.

<PAGE>

                                   ARTICLE 10

                                 MISCELLANEOUS

     10.1 ASSIGNMENT.

        (a) AFFILIATES. Warner may assign any of its rights or obligations under
this Agreement in any country to any Affiliates; provided, however, that such
assignment shall not relieve Warner of its responsibilities for performance of
its obligations under this Agreement, and further provided that if a proposed
assignment would have an adverse financial impact upon Interneuron (e.g., by
reason of changed tax treatment of payments due under this Agreement), such
assignment shall be subject to Interneuron' prior written consent.

        (b) MERGER, ACQUISITION OR SALE OF ASSETS. Subject to the terms hereof,
either Party may assign its rights or obligations under this Agreement to a non-
Affiliate only in connection with a merger or similar reorganization or the sale
of all or substantially all of its assets or the sale of all or substantially
all of its pharmaceutical and/or healthcare assets, or otherwise with the prior
written consent of the other Party.  This Agreement shall survive any such
merger or reorganization of either Party with or into, or such sale of assets
to, another party and no consent for such merger, reorganization or sale shall
be required hereunder; provided, that in the event of such merger,
reorganization or sale, no intellectual property rights of the acquiring
corporation shall be included in the technology licensed hereunder.

        (c) BINDING UPON SUCCESSORS AND ASSIGNS. This Agreement shall be binding
upon and inure to the benefit of the successors and permitted assigns of the
Parties.  Any assignment not in accordance with this Agreement shall be void.

     10.2 FORCE MAJEURE.   Neither Party shall lose any rights hereunder or be
liable to the other Party for damages or losses on account of failure of
performance by the defaulting Party if the failure is occasioned by government
action, war, fire, earthquake, explosion, flood, strike, lockout, embargo, act
of God, or any other similar or dissimilar cause beyond the control of the
defaulting Party, provided that the Party claiming force majeure has exerted all
reasonable efforts to avoid or remedy such force majeure.

     10.3  BANKRUPTCY PROVISION.  All rights and licenses granted by
Interneuron to Warner under or pursuant to this Agreement are, and shall
otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy
Code, licenses of rights to "intellectual property" as defined in Section 101 of
the Bankruptcy Code.  The parties agree that Warner, as exclusive licensee of
such rights under this Agreement, shall retain and may fully exercise all of its
rights and elections under the Bankruptcy Code.  The parties further agree that,
in the event of the commencement of a bankruptcy proceeding by or against
Interneuron under the Bankruptcy Code, Warner shall be entitled to a complete
duplicate of (or complete access to, as appropriate) any such intellectual
property and all embodiments of such intellectual property, and same, if not
already in its possession, shall be promptly delivered to Warner (i) upon any
such commencement of a bankruptcy proceeding, unless Interneuron elects to
continue to perform all

<PAGE>

of its obligations under this Agreement; or (ii) if not delivered under (i)
above, upon the rejection of this Agreement by or on behalf of Interneuron.

     10.4 FURTHER ACTIONS.   Each Party agrees to execute, acknowledge and
deliver such further instruments, and to do all such other acts, as may be
necessary or appropriate in order to carry out the purposes and intent of this
Agreement.

     10.5 NO TRADEMARK RIGHTS.   Except as otherwise provided herein, no right,
express or implied, is granted by the Agreement to use in any manner the name
Warner, Interneuron or any other trade name or trademark of the other Party or
its Affiliates in connection with the performance of the Agreement.

     10.6 NOTICES.   All notices hereunder shall be in writing and shall be
deemed given if delivered personally or by facsimile transmission (receipt
verified), telexed, mailed by registered or certified mail (return receipt
requested), postage prepaid, or sent by express courier service, to the Parties
at the following addresses (or at such other address for a Party as shall be
specified by like notice; provided, that notices of a change of address shall be
effective only upon receipt thereof).

If to Interneuron, addressed to: Interneuron Pharmaceuticals, Inc.
                                 99 Hayden Avenue, Suite 200
                                 Lexington, MA 02421-7966
                                 Attn:  Glenn L. Cooper, M.D., President and CEO
                                 Telephone:   781-861-8444
                                 Telecopy:    781-861-3830

If to Warner, addressed to:      Warner-Lambert Company
                                 201 Tabor Road
                                 Morris Plains, NJ  07950
                                 Attention: President, Pharmaceutical Division
                                 Telephone:  (973) 540-7259
                                 Telecopy:   (973) 540-3927

With a copy to:                  Warner-Lambert Company
                                 201 Tabor Road
                                 Morris Plains, NJ 07950
                                 Attention:  Vice President and
                                             General Counsel

     10.7 Waiver.   Except as specifically provided for herein, the waiver from
time to time by either of the Parties of any of their rights or their failure to
exercise any remedy shall not operate or be construed as a continuing waiver of
same or of any other of such Party's rights or remedies provided in this
Agreement.

     10.8 SEVERABILITY.   If any term, covenant or condition of this Agreement
or the application thereof to any Party or circumstance shall, to any extent, be
held to be invalid or unenforceable,

<PAGE>

then (i) the remainder of this Agreement, or the application of such term,
covenant or condition to the Parties or under circumstances other than those as
to which it is held invalid or unenforceable, shall not be affected thereby and
each term, covenant or condition of this Agreement shall be valid and be
enforced to the fullest extent permitted by law; and (ii) the Parties hereto
covenant and agree to renegotiate any such term, covenant or application thereof
in good faith in order to provide a reasonably acceptable alternative to the
term, covenant or condition of this Agreement or the application thereof that is
invalid or unenforceable, it being the intent of the Parties that the basic
purposes of this Agreement are to be effectuated.

     10.9 AMBIGUITIES.   Ambiguities, if any, in this Agreement shall not be
construed against any Party, irrespective of which Party may be deemed to have
authored the ambiguous provision.

     10.10 GOVERNING LAW.   This Agreement shall be governed by and interpreted
under the laws of the State of New Jersey without reference of rules or
principles relating to conflicts of laws.

     10.11 HEADINGS.   The Article and Section headings contained herein are for
the purposes of convenience only and are not intended to define or limit the
contents of said Articles or Sections.

     10.12 COUNTERPARTS.   This Agreement may be executed in two (2) or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

     10.13 ENTIRE AGREEMENT.   This Agreement including all Exhibits attached
hereto, and all documents delivered concurrently herewith, set forth all the
covenants, promises, agreements, warranties, representations, conditions and
understandings between the Parties hereto with respect to the subject matter
hereof and supersede and terminate all prior agreements and understanding
between the Parties as to such subject matter.  There are no covenants,
promises, agreements, warranties, representations, conditions or understandings,
either oral or written, between the Parties with respect to such subject matter
other than as set forth herein and therein.  No subsequent alteration,
amendment, change or addition to this Agreement shall be binding upon the
Parties hereto unless reduced to writing and signed by the respective authorized
officers of the Parties.

     10.14 USE OF NAMES.   Except as otherwise provided in this Agreement,
neither Party shall use the name of the other Party in relation to this
transaction in any public announcement, press release or other public document
without the consent of such other Party, which consent shall not be unreasonably
withheld or delayed; provided, however, that either Party may use the name of
the other Party in any document required to be filed to obtain Regulatory
Approval or to comply with applicable laws, rules or regulations.

<PAGE>

     IN WITNESS WHEREOF, the Parties have executed this License Agreement in
duplicate originals by their proper officers as of the Effective Date.

INTERNEURON PHARMACEUTICALS, INC.              WARNER-LAMBERT COMPANY

By: /s/ Glenn L. Cooper                         By: /s/ Peter B. Corr
    -------------------                             ------------------

Title: President and CEO                       Title: President, R&D
       -----------------                              ----------------

<PAGE>

                               LICENSE AGREEMENT

                                    BETWEEN

                       INTERNEURON PHARMACEUTICALS, INC.
                                      AND
                             WARNER-LAMBERT COMPANY

                             _______________, 1999

<PAGE>

EXHIBIT A:                                        STRUCTURE OF COMPOUND

USAN and International
non-proprietary name:    Pagoclone

Trade name:         not available

Code name:          RP 62955; IP 456

Chemical Name:      (+)-2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-
                    oxohexyl)phthalimidine; (+)-2-(7-chloro-1,8-naphthyridin-2-
                    yl)-2,3-dihydro-3-(5-methyl-2-oxohexyl)-1H-isoindol-1-one

                            [Diagram appears here]

                             *:  asymmetric carbon

Empirical formula:  C23H22ClN3O2

Molecular weight:   407.904

                                      A-1
<PAGE>

Exhibit B: List of patents
Interneuron/Warner-Lambert Agreement dated 12/23/99

                                    Table 1

                           Substance and Composition

<TABLE>
<CAPTION>

--------------------------------------------------------------------------------------------------

Country                       Filed            Published           Issued           Expiration
--------------------------------------------------------------------------------------------------
<S>                     <C>                <C>                <C>                <C>
South Africa                    *                  -                  *                  *
--------------------------------------------------------------------------------------------------
Germany                         *                  *                  *                  *
--------------------------------------------------------------------------------------------------
Australia                       *                  -                  *                  *
--------------------------------------------------------------------------------------------------
Austria                         *                  *                  *                  *
--------------------------------------------------------------------------------------------------
Belgium                         *                  *                  *                  *
--------------------------------------------------------------------------------------------------
Canada                          *                  -                  *                  *
--------------------------------------------------------------------------------------------------
South Korea                     *                  -                  *                  *
--------------------------------------------------------------------------------------------------
Denmark                         *                  -                  *                  *
--------------------------------------------------------------------------------------------------
Spain                           *                  *                  *                  *
--------------------------------------------------------------------------------------------------
United States                   *                  -                  *                  *
--------------------------------------------------------------------------------------------------
France                          *                  *                  *                  *
--------------------------------------------------------------------------------------------------
Greece                          *                  *                  *                  *
--------------------------------------------------------------------------------------------------
Ireland                         *                  -                  *                  *
--------------------------------------------------------------------------------------------------
Italy                           *                  *                  *                  *
--------------------------------------------------------------------------------------------------
Japan                           *                  -                  *                  *
--------------------------------------------------------------------------------------------------
Luxembourg                      *                  *                  *                  *
--------------------------------------------------------------------------------------------------
Mexico                          *                  -                  *                  *
--------------------------------------------------------------------------------------------------
New Zealand                     *                  -                  *                  *
--------------------------------------------------------------------------------------------------
Netherlands                     *                  *                  *                  *
--------------------------------------------------------------------------------------------------
Portugal                        *                  -                  *                  *
--------------------------------------------------------------------------------------------------
European Application            *                  *                  *                  *
--------------------------------------------------------------------------------------------------
United Kingdom                  *                  *                  *                  *
--------------------------------------------------------------------------------------------------
Sweden                          *                  *                  *                  *
--------------------------------------------------------------------------------------------------
Switzerland                     *                  *                  *                  *
--------------------------------------------------------------------------------------------------
</TABLE>

*CONFIDENTIAL TREATMENT REQUESTED

                                      B-1

Exhibit B: List of patents
Interneuron/Warner-Lambert Agreement dated 12/23/99

                                    Table 2

                             Process Resolution I

<TABLE>
<CAPTION>

-------------------------------------------------------------------------------------------------

Country                     Filed             Published           Issued           Expiration
-------------------------------------------------------------------------------------------------
<S>                   <C>                 <C>                <C>                <C>
South Africa                  *                   -                  *                  *
-------------------------------------------------------------------------------------------------
Australia                     *                   -                  *                  *
-------------------------------------------------------------------------------------------------
Canada                        *                   -                  -                  *
-------------------------------------------------------------------------------------------------
South Korea                   *                   *                  -                  *
-------------------------------------------------------------------------------------------------
France                        *                   *                  *                  *
-------------------------------------------------------------------------------------------------
Ireland                       *                   -                  *                  *
-------------------------------------------------------------------------------------------------
Mexico                        *                   -                  *                  *
-------------------------------------------------------------------------------------------------
New Zealand                   *                   -                  *                  *
-------------------------------------------------------------------------------------------------
PCT                           *                   *                  -                  -
-------------------------------------------------------------------------------------------------
</TABLE>

*CONFIDENTIAL TREATMENT REQUESTED
Received from Pepper Hamilton 7/14/19

                                      B-2

Exhibit B: List of patents
Interneuron/Warner-Lambert Agreement dated 12/23/99

                                    Table 3

                             Process Resolution II

<TABLE>
<CAPTION>

-------------------------------------------------------------------------------------------------

Country                       Filed            Published          Issued           Expiration
-------------------------------------------------------------------------------------------------
<S>                     <C>                 <C>              <C>                <C>
South Africa                    *                  -                 *                  *
-------------------------------------------------------------------------------------------------
Australia                       *                  -                 *                  *
-------------------------------------------------------------------------------------------------
Canada                          *                  -                 -                  *
-------------------------------------------------------------------------------------------------
South Korea                     *                  *                 -                  *
-------------------------------------------------------------------------------------------------
France                          *                  *                 *                  *
-------------------------------------------------------------------------------------------------
Ireland                         *                  *                 *                  *
-------------------------------------------------------------------------------------------------
Mexico                          *                  -                 *                  *
-------------------------------------------------------------------------------------------------
New Zealand                     *                  -                 *                  *
-------------------------------------------------------------------------------------------------
European Application            *                  *                 -                  -
-------------------------------------------------------------------------------------------------
PCT                             *                  *                 -                  -
-------------------------------------------------------------------------------------------------
Mexico                          -                  -                 *                  -
-------------------------------------------------------------------------------------------------
</TABLE>

*CONFIDENTIAL TREATMENT REQUESTED
Received from Pepper Hamilton 7/14/19

                                      B-3

Exhibit B: List of patents
Interneuron/Warner-Lambert Agreement dated 12/23/99

                                    Table 4

                            Process Resolution III

<TABLE>
<CAPTION>

-------------------------------------------------------------------------------------------------
Country                       Filed            Published          Issued           Expiration
-------------------------------------------------------------------------------------------------
<S>                     <C>                 <C>              <C>                <C>
South Africa                    *                  -                 *                  *
-------------------------------------------------------------------------------------------------
Australia                       *                  -                 *                  *
-------------------------------------------------------------------------------------------------
Canada                          *                  -                 -                  *
-------------------------------------------------------------------------------------------------
South Korea                     *                  *                 -                  *
-------------------------------------------------------------------------------------------------
France                          *                  *                 *                  *
-------------------------------------------------------------------------------------------------
Ireland                         *                  *                 *                  *
-------------------------------------------------------------------------------------------------
Mexico                          *                  -                 *                  *
-------------------------------------------------------------------------------------------------
New Zealand                     *                  -                 *                  *
-------------------------------------------------------------------------------------------------
European Application            *                  *                 -                  -
-------------------------------------------------------------------------------------------------
PCT                             *                  *                 -                  -
-------------------------------------------------------------------------------------------------
</TABLE>

*CONFIDENTIAL TREATMENT REQUESTED
Received from Pepper Hamilton 7/14/19

                                      B-4

Exhibit B: List of patents
Interneuron/Warner-Lambert Agreement dated 12/23/99

                                    Table 5

                             Process Resolution IV

<TABLE>
<CAPTION>

-------------------------------------------------------------------------------------------------

Country                       Filed            Published          Issued           Expiration
-------------------------------------------------------------------------------------------------
<S>                     <C>                 <C>              <C>                <C>
South Africa                    *                  -                 *                  *
-------------------------------------------------------------------------------------------------
Australia                       *                  -                 *                  *
-------------------------------------------------------------------------------------------------
Canada                          *                  -                 -                  *
-------------------------------------------------------------------------------------------------
South Korea                     *                  *                 -                  *
-------------------------------------------------------------------------------------------------
France                          *                  *                 *                  *
-------------------------------------------------------------------------------------------------
Ireland                         *                  *                 *                  *
-------------------------------------------------------------------------------------------------
Mexico                          *                  -                 *                  *
-------------------------------------------------------------------------------------------------
New Zealand                     *                  -                 *                  *
-------------------------------------------------------------------------------------------------
European Application            *                  *                 -                  -
-------------------------------------------------------------------------------------------------
PCT                             *                  *                 -                  -
-------------------------------------------------------------------------------------------------
</TABLE>

*CONFIDENTIAL TREATMENT REQUESTED
Received from Pepper Hamilton 7/14/19

                                      B-5

Exhibit B: List of patents
Interneuron/Warner-Lambert Agreement dated 12/23/99

                                   Table 5a

                             Process Resolution IV

<TABLE>
<CAPTION>

Country                        Filed             Published           Issued           Expiration
----------------------------------------------------------------------------------------------------
<S>                     <C>                 <C>              <C>                <C>
Europe                           *                   -                  *                  *
----------------------------------------------------------------------------------------------------
United States                    *                   -                  *                  *
----------------------------------------------------------------------------------------------------
Japan                            *                   -                  *                  *
----------------------------------------------------------------------------------------------------
</TABLE>

*CONFIDENTIAL TREATMENT REQUESTED
Received from Pepper Hamilton 7/14/19

                                      B-6

Exhibit B: List of patents
Interneuron/Warner-Lambert Agreement dated 12/23/99

                                    Table 6

                      Metabolites, Process and Isolation

<TABLE>
<CAPTION>

-----------------------------------------------------------------------------------------------------------
Country                           Filed              Published             Issued            Expiration
-----------------------------------------------------------------------------------------------------------
<S>                       <C>                    <C>                 <C>                 <C>
South Africa                        *                    *                   *                   *
-----------------------------------------------------------------------------------------------------------
Austria                             *                    *                   *                   *
-----------------------------------------------------------------------------------------------------------
Belgium                             *                    *                   *                   *
-----------------------------------------------------------------------------------------------------------
Canada                              *                    -                   -                   *
-----------------------------------------------------------------------------------------------------------
Denmark                             *                    *                   *                   *
-----------------------------------------------------------------------------------------------------------
Spain                               *                    *                   *                   *
-----------------------------------------------------------------------------------------------------------
United States                       *                    -                   *                   *
-----------------------------------------------------------------------------------------------------------
United States                       *                    -                   *                   *
-----------------------------------------------------------------------------------------------------------
United States                       *                    -                   *                   *
-----------------------------------------------------------------------------------------------------------
France                              *                    *                   *                   *
-----------------------------------------------------------------------------------------------------------
France                              *                    *                   *                   *
-----------------------------------------------------------------------------------------------------------
Greece                              *                    *                   *                   *
-----------------------------------------------------------------------------------------------------------
Ireland                             *                    *                   *                   *
-----------------------------------------------------------------------------------------------------------
Italy                               *                    *                   *                   *
-----------------------------------------------------------------------------------------------------------
Japan                               *                    -                   -                   *
-----------------------------------------------------------------------------------------------------------
Luxembourg                          *                    *                   *                   *
-----------------------------------------------------------------------------------------------------------
Netherlands                         *                    *                   *                   *
-----------------------------------------------------------------------------------------------------------
Portugal                            *                    *                   *                   *
-----------------------------------------------------------------------------------------------------------
European Application                *                    *                   *                   *
-----------------------------------------------------------------------------------------------------------
PCT                                 *                    *                   -                   *
-----------------------------------------------------------------------------------------------------------
United Kingdom                      *                    *                   *                   *
-----------------------------------------------------------------------------------------------------------
Sweden                              *                    *                   *                   *
-----------------------------------------------------------------------------------------------------------
Switzerland                         *                    *                   *                   *
-----------------------------------------------------------------------------------------------------------
</TABLE>

*CONFIDENTIAL TREATMENT REQUESTED
Received from Pepper Hamilton 7/14/19

                                      B-7

<PAGE>
Exhibit B: List of patents
Interneuron/Warner-Lambert Agreement dated 12/23/99

                                    Table 7

                     Additional Methods of Use Applications

<TABLE>
<CAPTION>

       Country                Filed            Published           Issued           Expiration
--------------------------------------------------------------------------------------------------
<S>                       <C>                    <C>                 <C>                 <C>

United States                   *                  -                  -                  -
--------------------------------------------------------------------------------------------------
</TABLE>

Updated on September 16, to include new application (above).
Received from Pepper Hamilton 7/14/19

                                      B-8
<PAGE>

                      Exhibit C: Contracts and Agreements
              Interneuron/Warner-Lambert Agreement dates 12/23/99
                 List of Contracts/agreements/POs for pagoclone

<TABLE>
<CAPTION>
                     VENDOR                                         DESCRIPTION
---------------------------------------------------------------------------------------------------------
<C>    <S>                                 <C>
    1  Albany Molecular                    Re-certification of pagoclone reference standard
---------------------------------------------------------------------------------------------------------
    2  Albany Molecular Research           Storage & Bi-Annual Analysis
---------------------------------------------------------------------------------------------------------
    3  Imperial College of Science         PET Study 6 volunteers (IP456-008)
       Tech.& Medicine
---------------------------------------------------------------------------------------------------------
    4  Phoenix International Life          Method development & validation
---------------------------------------------------------------------------------------------------------
    5  PPD Pharmaco                        Soft-gel Stability Program
---------------------------------------------------------------------------------------------------------
    6  PPD Pharmaco                        Dev & validation of a chiral assay for "total & "free" pag
---------------------------------------------------------------------------------------------------------
    7  PPD Pharmaco                        Release testing & stability testing
---------------------------------------------------------------------------------------------------------
    8  PPD Pharmaco                        Stability testing of drug substance
---------------------------------------------------------------------------------------------------------
    9  PPD Pharmaco                        Stability testing of soft-gel capsule lot#E900882 & E900883
---------------------------------------------------------------------------------------------------------
   10  PPD Pharmaco                        Stability testing of pagoclone surfactant formulation
---------------------------------------------------------------------------------------------------------
   11  PPD Pharmaco                        Stability testing of drug substance, Batch P112-281-2
---------------------------------------------------------------------------------------------------------
   12  PPD Pharmaco                        LC/MS validation of pagoclone protein
---------------------------------------------------------------------------------------------------------
   13  PPD Pharmaco                        Stability testing of pagoclone, Batch P132-13-1
---------------------------------------------------------------------------------------------------------
   14  PPD Pharmaco                        Stability studies in various excipients
---------------------------------------------------------------------------------------------------------
   15  PPD Pharmaco                        Stability storage & analysis of Pagoclone
---------------------------------------------------------------------------------------------------------
   16  Regis Technologies                  Pagoclone method of development
---------------------------------------------------------------------------------------------------------
   17  Regis Technologies                  Pagoclone synthesis
---------------------------------------------------------------------------------------------------------
   18  Regis Technologies                  Pagoclone scale-up
---------------------------------------------------------------------------------------------------------
   19  Regis Technologies                  Pagoclone GMP manufacture
---------------------------------------------------------------------------------------------------------
   20  Wisconsin Analytical                Pagoclone Soft Gel Stability Program
---------------------------------------------------------------------------------------------------------
   21  Wisconsin Analytical                Softgel Stability (Blister cards)
---------------------------------------------------------------------------------------------------------
</TABLE>

                                      C-1

<PAGE>

Exhibit D:    Interneuron-RPR License Agreement

(Filed as exhibit 10.52 to Registrant's Registration statement on Form S-3 or
Amendment No.1 (File No. 33-75826))

                                      D-1
<PAGE>

                                LIST OF EXHIBITS

EXHIBIt A:  STRUCTURE OF COMPOUND

EXHIBIT B:  LIST OF PATENTS

EXHIBIT C:  CONTRACTS AND AGREEMENTS

EXHIBIT D:  INTERNEURON-RPR LICENSE AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00001-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00001-of-00352.parquet"}]]